September 9, 2021
Kyowa Kirin has been granted exclusive rights to develop and commercialize Dutch drug maker AM-Pharma’s investigational agent ilofotase alfa in Japan for the treatment of sepsis-associated acute kidney injury (SA-AKI), the two companies said on September 8. Under their licensing...read more